DcR1 antibody

Catalog No. ABIN1169230

This Mouse Monoclonal antibody specifically detects DcR1 in FACS and ICC. It exhibits reactivity toward Human. It has been mentioned in 5+ publications

Quick Overview for DcR1 antibody (ABIN1169230)

Target: DcR1 (TNFRSF10C) (Tumor Necrosis Factor Receptor Superfamily, Member 10c (TNFRSF10C))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This DcR1 antibody is un-conjugated

Application: Flow Cytometry (FACS), Immunocytochemistry (ICC)

Clone: HS301

Product Details anti-DcR1 Antibody

Specificity: Recognizes human TRAIL-R3.

Cross-Reactivity: Human

Cross-Reactivity (Details): Does not cross-react with human TRAIL-R1, -R2 or -R4.

Purification: Purified from concentrated hybridoma tissue culture supernatant.

Purity: >95 % (SDS-PAGE)

Immunogen: Recombinant human TRAIL-R3 (DcR1).

Isotype: IgG1

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: Lot specific

Buffer: In PBS containing 10 % glycerol and 0.02 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 1 year after receipt when stored at -20°C.

Expiry Date: 12 months

References for anti-DcR1 antibody (ABIN1169230)

Hartwig, Montinaro, von Karstedt, Sevko, Surinova, Chakravarthy, Taraborrelli, Draber, Lafont, Arce Vargas, El-Bahrawy, Quezada, Walczak: "The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2." in: Molecular cell, Vol. 65, Issue 4, pp. 730-742.e5, (2017) (PubMed).

Wachter, Sprick, Hausmann, Kerstan, McPherson, Stassi, Bröcker, Walczak, Leverkus: "cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes." in: The Journal of biological chemistry, Vol. 279, Issue 51, pp. 52824-34, (2004) (PubMed).

Secchiero, Melloni, Heikinheimo, Mannisto, Di Pietro, Iacone, Zauli: "TRAIL regulates normal erythroid maturation through an ERK-dependent pathway." in: Blood, Vol. 103, Issue 2, pp. 517-22, (2004) (PubMed).

Ganten, Haas, Sykora, Stahl, Sprick, Fas, Krueger, Weigand, Grosse-Wilde, Stremmel, Krammer, Walczak: "Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs." in: Cell death and differentiation, Vol. 11 Suppl 1, pp. S86-96, (2004) (PubMed).

Washburn, Weigand, Grosse-Wilde, Janke, Stahl, Rieser, Sprick, Schirrmacher, Walczak: "TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 170, Issue 4, pp. 1814-21, (2003) (PubMed).

Target Details for DcR1

Target: DcR1 (TNFRSF10C) (Tumor Necrosis Factor Receptor Superfamily, Member 10c (TNFRSF10C))

Alternative Name: TRAIL-R3

Background: TRAIL-R3 is a receptor for the cytotoxic ligand TRAIL. It lacks a cytoplasmic death domain and hence is not capable of inducing apoptosis. Protects cells against TRAIL mediated apoptosis by competing with TRAIL-R1 and R2 for binding to the ligand.

UniProt: O14798

Pathways: Apoptosis